Russia to launch social media blitz for Sputnik V, India,Russia in touch for production of vaccine
New Delih, Nov 9 : India and Russia are in touch for production of COVID-19 vaccine ‘Sputnik V’ and Russia will transfer ’technology to India and Indian drug manufacturers for production of the vaccine .Four Indian companies have shown interest, official sources said here on Monday .
In a social media blitz, Russia will launch a campaign across all social media platforms all over the world to provide up-to-date information and raise awareness about ‘Sputnik V’ using #Sputnik V hashtag.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the Gamaleya National Center for Microbiology and Epidemiology, supported by international partners, will initiate the campaign focusing on the progress of Sputnik V clinical trials, production and mass vaccination in different countries, the Russian embassy here said.
Sputnik V social media channels will also become the main platform for exclusive delivery of major news about the vaccine, publication of latest data on the number of people vaccinated and vaccine production data. The channels will also carry live events with major announcements and expert commentaries.
The information about Sputnik V will be available on the following platforms:
On Twitter – @sputnikvaccine
On Facebook – @sputnikvaccine
On Instagram – @sputnik_vaccine
On Youtube – Sputnik V
Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. It currently ranks among top-10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Trade Organization’s (WHO) list. Russia submitted applications to the WHO for accelerated registration and prequalification of Sputnik V.
The ongoing Sputnik V post-registration clinical trial in Russia involves 40,000 volunteers. Clinical trials of Sputnik V have been announced in India, the UAE, Venezuela and Belarus.
Official sources said Russia has been in talks with the External Affairs Ministry and some vaccine manufacturers for mass production of the vaccine in India. Following Russia’s request, India is considering conducting clinical trials, regulatory facilitation and manufacturing of the vaccine and various scientific bodies are looking into it.
There has been positive movement on both fronts, the sources said and added that four Indian companies had shown interest while discussions were on with several other companies. .
Seven Indian companies including Zydus Cadilla, Bharat Biotech, Panacea Biotech and Mynvax are among the domestic pharma companies working on producing Corona vaccine in India. Serum Institute of India has expressed the hope to develop the COVID vaccine by year end.
The sources said Indian companies have sought technical details about the vaccine from the RDIF for its production in India. Indian Ambassador in Moscow D B Venkatesh Verma has also held discussions in September with RDIF officials in this regard, the sources said.
RDIF has said it plans to start mass production of the vaccine in India, South Korea, Brazil, Saudi Arabia, Turkey and Cuba.